Related Experiment Video

Updated: Jun 11, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

[Study on the genetic alterations in MTX-resistant cells by differential polymerase chain reaction]

Yu Zhang1, Xin-Yu Deng, Xiao-Ling Zhang

  • 1Laboratory of Medical Genetics, Harbin Medical University, Harbin 150086, China. zhangyu@yahoo.com.cn

Yi Chuan Xue Bao = Acta Genetica Sinica
|June 19, 2003
PubMed

Insights

Gene amplification drives drug resistance. In mouse cells, dihydrofolate reductase (DHFR) gene amplification and overexpression contribute to methotrexate (MTX) resistance, independent of c-myc and p53 alterations.

Area of Science:

  • Molecular biology
  • Genetics
  • Cancer research

Context:

  • Gene amplification is a key mechanism in drug resistance.
  • Methotrexate (MTX) resistance is a significant challenge in cancer therapy.
  • Understanding resistance mechanisms is crucial for developing effective treatments.

Purpose:

  • To investigate the molecular genetic basis of MTX resistance in mouse cells.
  • To determine the role of DHFR gene amplification and overexpression in MTX resistance.
  • To explore potential correlations between DHFR amplification and the status of c-myc and p53 genes.

Summary:

  • Differential PCR revealed DHFR gene amplification and overexpression in MTX-resistant mouse cells.
  • No amplification or overexpression of the c-myc gene was detected.
  • p53 copy number remained unaltered, with increased mRNA levels suggesting normal function.
  • These findings indicate that c-myc and p53 status are not correlated with DHFR amplification in MTX resistance.

Impact:

  • Highlights DHFR amplification as a critical factor in MTX resistance.
  • Suggests that other, yet unidentified, molecular alterations facilitate DHFR amplification.
  • Provides a foundation for further research into novel therapeutic targets for overcoming MTX resistance.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...